Cost Pushback Limiting Hepatitis C Drug Utilization
Executive Summary
Study finds 22% of patients prescribed drug therapy for HCV were not started on care or delayed 150-plus days beyond the writing of the prescription. Coverage decisions don't seem to be linked clearly to disease severity, but denials were higher among Medicaid patients and among certain private-sector plans.